(SeaPRwire) –
For years, the oncology world has treated EGFR-mutated non-small cell lung cancer with a rigid adherence to single-agent tyrosine kinase inhibitors. The prevailing assumption was that a highly selective TKI like osimertinib was the gold standard. This view has now fractured. The SANOVO trial data presented at ESMO 2026 exposes a critical blind spot in precision medicine. Patients with co-occurring MET overexpression were effectively being undertreated with monotherapy. The anxiety is no longer about finding a better single drug. It is about acknowledging that resistance mechanisms often exist from day one. The industry must pivot from reactive treatment to proactive, combinatorial strategies.
The data from the Phase III SANOVO study is unambiguous. In treatment-naive patients with EGFR-mutated NSCLC and MET overexpression, the combination of savolitinib and osimertinib reduced the risk of disease progression or death by 44% in the overall population. The benefit was even more pronounced in the high MET overexpression group. Here, the risk reduction reached 55%. Median progression-free survival jumped to 24.9 months with the combination. This stands in stark contrast to the 11.1 months observed in the high MET subgroup receiving osimertinib alone. The overall survival endpoint also shows a meaningful improvement. The hazard ratio for OS was 0.48, extending median survival by 9.6 months compared to the control arm. These are not marginal gains. They represent a fundamental shift in what is clinically achievable.
Commercially, this trial redefines the value proposition of upfront combination therapy. Historically, combinations were reserved for later lines due to toxicity concerns and cost. SANOVO proves that all-oral, dual-targeted approaches can be initiated at diagnosis. This preserves quality of life while extending survival. For HUTCHMED and AstraZeneca, this validates a multi-year investment in biomarker-driven strategies. The end-game is a market where standard-of-care decisions are dictated by comprehensive molecular profiling at diagnosis. Providers will move away from sequential trial-and-error. They will adopt targeted combinations based on MET status. The result is a longer-lasting efficacy window before resistance emerges. This extends the duration of care and alters drug reimbursement models. Payers must now consider upfront combination therapy as the primary baseline for this patient cohort.